Clinical Report: Optimizing Eligibility Evaluation for Alzheimer's Disease Treatment

Overview

This study evaluates the Digital Clock and Recall (DCR™) method as a rapid digital cognitive assessment to predict Mini-Mental State Examination (MMSE) scores. The machine learning model demonstrated comparable precision to traditional MMSE administration.

Background

The recent approval of anti-amyloid disease-modifying therapies (DMTs) for Alzheimer's disease (AD) necessitates effective screening methods for treatment eligibility. Traditional cognitive assessments like the MMSE are time-consuming and may perpetuate health disparities due to educational and cultural biases. This study explores a digital alternative.

Data Highlights

Key Findings

• The DCR™ method predicted MMSE scores with an RMSE of 2.43 in the Bio-Hermes-001 test set.
• External validation in the Apheleia cohort showed an RMSE of 2.62, indicating robust generalizability.
• Prediction errors were comparable across racial and ethnic groups, suggesting fairness in the model's predictions.
• Significant differences in prediction errors were observed only for sex and age in the Apheleia cohort.
• The DCR™ method offers a rapid and equitable alternative to traditional MMSE administration.

Clinical Implications

The DCR™ method could assist in identifying patients eligible for DMTs.

Conclusion

The DCR™ method represents an advancement in cognitive assessment for Alzheimer's disease.

Related Resources & Content

1. Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine, 2023 -- Title
2. Trial of Donanemab in Early Symptomatic Alzheimer Disease | JAMA, 2023 -- Title
3. Donanemab: Appropriate use recommendations - PMC, 2023 -- Title
4. Systematic Review of Brief Cognitive Screening Tools for Identifying Dementia and Mild Cognitive Impairment in Illiterate and Low‐Educated Populations, 2024 -- Title
5. npj Digital Medicine — Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease
6. Frontiers in Neurology — From cognitive screening to digital phenotyping: rethinking early detection of cognitive impairment in primary care
7. npj Digital Medicine — Systematic Evaluation of Wearable EEG Technology for Identifying Mild Cognitive Impairment
8. npj Digital Medicine — Digital Cognitive Evaluation for Aging and Dementia via the Oxford Cognitive Testing Portal (OCTAL)
9. Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease
10. From cognitive screening to digital phenotyping: rethinking early detection of cognitive impairment in primary care
11. Systematic Evaluation of Wearable EEG Technology for Identifying Mild Cognitive Impairment
12. Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine
13. Trial of Donanemab in Early Symptomatic Alzheimer Disease
14. Donanemab: Appropriate use recommendations - PMC
15. “Systematic Review of Brief Cognitive Screening Tools for Identifying Dementia and Mild Cognitive Impairment in Illiterate and Low‐Educated Populations” - Zegarra‐Valdivia - 2024 - Alzheimer's & Dementia - Wiley Online Library
16. Cognitive and Functional Assessment for MCI or Memory Loss | AAN
17. Diagnostic accuracy of digital clock drawing test for Alzheimer disease and mild cognitive impairment | npj Digital Medicine